Blueprint Medicines’ (BPMC) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reissued their buy rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a research report report published on Friday morning,Benzinga reports. The firm currently has a $135.00 price objective on the biotechnology company’s stock. BPMC has been the subject of several other reports. JPMorgan Chase & Co. raised their price objective […]
HC Wainwright reissued their buy rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a research report report published on Friday morning,Benzinga reports. The firm currently has a $135.00 price objective on the biotechnology company’s stock. BPMC has been the subject of several other reports. JPMorgan Chase & Co. raised their price objective […]
